FDA to review AstraZeneca-Bristol's diabetes drug again

07/29/2013 | Medscape (free registration)

The FDA has accepted AstraZeneca and Bristol-Myers Squibb's resubmission of a marketing application for dapagliflozin for treatment of type 2 diabetes. A decision is expected by Jan. 11. The sodium-glucose co-transporter 2 inhibitor has been approved for sale in Europe and is being sold in Brazil and Australia, among other nations.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care